Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer

Hanagiri, Takeshi; Takenaka, Masaru; Oka, Soich; Shigematsu, Yoshiki; Nagata, Yoshika; Shimokawa, Hidehiko; Uramoto, Hidetaka; Tanaka, Fumihiro

doi:10.1186/1749-8090-6-144

Cited by 13 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of ALK fusions was higher than reported. In addition, we found that the tumors exhibited mainly poor and poor-moderate differentiation, which was consistent with previous studies [ 9 , 10 ].…”

Section: Discussionsupporting

confidence: 93%

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

et al. 2016

View full text Add to dashboard Cite

Lung cancer with mediastinal lymph node metastasis is more likely to develop recurrence and metastasis after complete resection and targeted therapy is a promising treatment strategy. We performed amplification refractory mutation system (ARMS) fluorescence quantitative PCR to detect the gene status of EGFR, ALK, ROS1 and RET in resected samples from 280 patients who were confirmed to have primary lung adenocarcinomas with N1-N2 lymph node metastasis. Of the 280 patients enrolled, the frequency of EGFR mutations, ALK fusions, ROS1 fusions, RET fusions and no mutations was 42.9%, 10.7%, 1.8%, 3.6% and 42.9%, respectively. Five patients exhibited the coexistence of the EGFR and ALK alterations. ALK, ROS1 and RET fusions were mutually exclusive. The frequency of EGFR mutation was significantly lower among patients with poor differentiation, while the rates of ALK and ROS1 fusions were the opposite. RET fusions also tended to be more prevalent in poorly differentiated patients. EGFR and ALK double positive tumors were characterized by significantly smaller size compared with those had single gene alteration. Our study comprehensively analyzed the distinct and common clinicopathologic characteristics according to genotypes of the cohort, which should help in categorizing patients for efficient screening.

show abstract

Section: Discussionsupporting

confidence: 93%

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…They emphasised that surgical treatment can be preferred in patients with N2 stage with one or two involved lymphatic nodes. 30 Also Legras et al confirmed a prognostic value of the number of involved N2 lymphatic nodes, 31 whereas Sezan et al made conflicting conclusions. 32 …”

Section: Discussionmentioning

confidence: 99%

Prognostic Factors Determining Survival of Patients Operated for Non-Small Cell Lung Cancer with Consideration Given to Morphological Parameters of Blood

Łochowski

Łochowska

Chałubińska-Fendler

et al. 2021

CMAR

View full text Add to dashboard Cite

“…Lobectomy may be safely performed following induction therapy while pneumonectomy may carry a high and possibly unacceptable rate of perioperative mortality [23,24]. This retrospective study tried to clarify the prognostic importance of the type of pulmonary resection in patients with p-stage III/N 2 NSCLC, who underwent complete dissection of the mediastinal lymph nodes.…”

Section: Discussionmentioning

confidence: 99%

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer

Yan

Wei

et al. 2013

J Cardiothorac Surg

View full text Add to dashboard Cite

BackgroundPathological stage III/N2 non-small cell lung cancer (NSCLC) is heterogeneous, and the optimal prognostic marker for survival remains unclear in Chinese patients. The aim of the present study was to assess the prognostic value of the clinicopathologic features and excision repair cross-complementing group-1 (ERCC1) in resected p-stage III/N2 NSCLC patients that received cisplatin-based adjuvant chemotherapy.MethodsClinical data concerning 115 patients with histopathologically confirmed stage III/N2 NSCLC who underwent a complete resection were reviewed retrospectively. All patients received cisplatin-based adjuvant chemotherapy. The protein expression levels for ERCC1 were immunohistochemically examined in 115 patients. The relationship between the ERCC1 protein expression level and the clinical outcomes of the patients was then observed.ResultsThe 5-year survival rate and median survival time of patients with pathological stage III/N2 NSCLC after surgery and postoperative chemotherapy was 27.0% and 28.0 months, respectively. Survival of patients with ERCC1 negative tumors was significantly longer than those with ERCC1 positive tumors (p = 0.004). However, it was not entirely clear whether adjuvant chemotherapy with cisplatin-based agents was beneficial for ERCC1-negative patients with p-stage III/N2. A multivariate analysis of survival in patients with stage III/N2 NSCLC showed that surgical procedure (pneumonectomy vs. lobectomy; p = 0.001), number of involved lymph nodes (≤5 vs. >5; p = 0.001) and ERCC1 protein expression (negative vs. positive; p = 0.012) were significant prognostic factors. In addition, the prognosis of patients with skip mediastinal lymph node metastasis showed a tendency for improved survival, but this was no significant (p = 0.432).ConclusionsFindings from this retrospective study suggested that the number of involved lymph nodes and the type of pulmonary resection are significant and independent prognosis factors in patients with p-stage III/N2 NSCLC. In addition, it was found that ERCC1 protein expression might play an important role in the prognosis of p-stage III/N2 NSCLC patients treated with cisplatin-based adjuvant chemotherapy.

show abstract

Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer

Cited by 13 publications

References 31 publications

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis

Prognostic Factors Determining Survival of Patients Operated for Non-Small Cell Lung Cancer with Consideration Given to Morphological Parameters of Blood

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer

Contact Info

Product

Resources

About